Penumbra - PEN Stock Forecast, Price & News

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Wall Street Analyst Weigh In

PEN has been the subject of a number of recent research reports. William Blair reissued an "outperform" rating on shares of Penumbra in a research report on Tuesday, May 3rd. Citigroup decreased their target price on Penumbra from $280.00 to $220.00 in a research report on Tuesday, May 17th. Canaccord Genuity Group decreased their target price on Penumbra from $244.00 to $189.00 and set a "buy" rating for the company in a research report on Friday, August 5th. BTIG Research cut their price target on Penumbra from $272.00 to $213.00 and set a "buy" rating for the company in a report on Monday, July 18th. Finally, Wells Fargo & Company cut their price target on Penumbra from $321.00 to $265.00 in a report on Wednesday, May 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Penumbra has a consensus rating of "Moderate Buy" and an average price target of $218.78.

Penumbra Price Performance

NYSE:PEN traded up $2.67 during trading hours on Monday, hitting $174.69. 171,439 shares of the company's stock traded hands, compared to its average volume of 302,808. The firm has a market cap of $6.62 billion, a P/E ratio of -335.53 and a beta of 0.73. Penumbra has a 52 week low of $114.86 and a 52 week high of $293.20. The business's fifty day simple moving average is $134.43 and its two-hundred day simple moving average is $172.44. The company has a quick ratio of 2.90, a current ratio of 4.93 and a debt-to-equity ratio of 0.03.

Penumbra (NYSE:PEN - Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.07. Penumbra had a positive return on equity of 0.97% and a negative net margin of 2.40%. The company had revenue of $208.30 million during the quarter, compared to analyst estimates of $206.24 million. During the same quarter last year, the company earned $0.21 earnings per share. The firm's quarterly revenue was up 13.0% on a year-over-year basis. On average, research analysts anticipate that Penumbra will post 0.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Penumbra news, Director Thomas Wilder sold 248 shares of Penumbra stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $123.64, for a total transaction of $30,662.72. Following the completion of the sale, the director now owns 462 shares of the company's stock, valued at $57,121.68. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold a total of 451 shares of company stock valued at $57,968 over the last 90 days. Insiders own 5.50% of the company's stock.